[go: up one dir, main page]

MX2010011047A - Derivados de tienopiridonas como activadores de proteina cinasa activada por amp (ampk). - Google Patents

Derivados de tienopiridonas como activadores de proteina cinasa activada por amp (ampk).

Info

Publication number
MX2010011047A
MX2010011047A MX2010011047A MX2010011047A MX2010011047A MX 2010011047 A MX2010011047 A MX 2010011047A MX 2010011047 A MX2010011047 A MX 2010011047A MX 2010011047 A MX2010011047 A MX 2010011047A MX 2010011047 A MX2010011047 A MX 2010011047A
Authority
MX
Mexico
Prior art keywords
ampk
activators
protein kinase
activated protein
thienopyridone derivatives
Prior art date
Application number
MX2010011047A
Other languages
English (en)
Inventor
Daniel Cravo
Sophie Hallakou-Bozec
Christine Charon
Franck Lepifre
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010011047(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2010011047A publication Critical patent/MX2010011047A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I) (ver fórmula I) en donde R1, R2 y R3 son como se definen en la reivindicación 1, incluyendo sus composiciones farmacéuticas y su uso en el tratamiento y/o la prevención de enfermedades y trastornos modulados por agonistas de AMP. La invención también se refiere a intermediarios y a un método de preparación de compuestos de la fórmula (I).
MX2010011047A 2008-04-11 2009-03-17 Derivados de tienopiridonas como activadores de proteina cinasa activada por amp (ampk). MX2010011047A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290364 2008-04-11
PCT/EP2009/001937 WO2009124636A1 (en) 2008-04-11 2009-03-17 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Publications (1)

Publication Number Publication Date
MX2010011047A true MX2010011047A (es) 2010-10-26

Family

ID=40671017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011047A MX2010011047A (es) 2008-04-11 2009-03-17 Derivados de tienopiridonas como activadores de proteina cinasa activada por amp (ampk).

Country Status (25)

Country Link
US (1) US8563729B2 (es)
EP (1) EP2262500B1 (es)
JP (1) JP5592348B2 (es)
KR (1) KR101630466B1 (es)
CN (1) CN101998853B (es)
AU (1) AU2009235784B2 (es)
BR (1) BRPI0910439B8 (es)
CA (1) CA2721025C (es)
CO (1) CO6300954A2 (es)
DK (1) DK2262500T3 (es)
EA (1) EA017756B1 (es)
EC (1) ECSP10010599A (es)
ES (1) ES2584278T3 (es)
HR (1) HRP20160907T1 (es)
HU (1) HUE027857T2 (es)
IL (1) IL208067A (es)
MX (1) MX2010011047A (es)
MY (1) MY155836A (es)
NZ (1) NZ589136A (es)
PL (1) PL2262500T3 (es)
PT (1) PT2262500T (es)
SI (1) SI2262500T1 (es)
UA (1) UA103321C2 (es)
WO (1) WO2009124636A1 (es)
ZA (1) ZA201008050B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2280952B1 (en) * 2008-05-05 2012-06-27 Merck Patent GmbH Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
RS53282B (sr) * 2009-12-29 2014-08-29 Poxel Tieno (2,3-b) piridindion ampk aktivatori i njihove terapeutske upotrebe
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011121109A1 (en) 2010-04-02 2011-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
RU2013114184A (ru) 2010-09-01 2014-10-10 Байер Интеллектуэль Проперти Гмбх Гербицидно-активные кетосультамы и дикетопиридины
CN103517896B (zh) * 2011-03-07 2016-09-21 葛兰素史密斯克莱有限责任公司 喹啉酮衍生物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
US9827222B2 (en) * 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
US10143703B2 (en) 2014-01-02 2018-12-04 Massachusetts Eye And Ear Infirmary Treating ocular neovascularization
CN105037321A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途
CN104892569A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途
CN104945369A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104892568A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途
CN105037322A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环和烷氧苯结构的黄原酸酯类化合物、其制备方法及用途
CN104945370A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926757A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途
CN105001194A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一种含氨基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104945372A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN105001181A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一类双酰基苄胺类的ampk激活剂、其制备方法及用途
CN105037296A (zh) * 2015-06-24 2015-11-11 佛山市赛维斯医药科技有限公司 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104926755A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途
CN104945371A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926756A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途
HRP20210895T1 (hr) * 2015-06-25 2021-08-20 University Health Network Inhibitori hpk1 i metode za njihovo korištenje
WO2017055925A2 (en) 2015-09-30 2017-04-06 Instituto De Medicina Molecular Methods for attenuating parasite virulence
US20190350955A1 (en) 2016-06-30 2019-11-21 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of cardiomyopathies
CN113166168A (zh) * 2018-11-16 2021-07-23 博希尔公司 噻吩并吡啶酮衍生物的一水合钾盐及其制备方法
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
US11850238B2 (en) * 2020-03-26 2023-12-26 Poxel Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy
FI4125887T3 (fi) * 2020-04-02 2024-05-03 Poxel Tienopyridiinijohdannaisen käyttö autosomaalisen dominantin polykystisen munuaissairauden (adpkd) hoidossa
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
WO2023092094A2 (en) 2021-11-19 2023-05-25 The Broad Institute, Inc. Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA903588B (en) 1989-05-16 1991-02-27 Merrell Dow Pharma Excitatory amino acid antagonists
DE4444815A1 (de) 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
KR20100115789A (ko) 2008-02-04 2010-10-28 머큐리 테라퓨틱스, 인코포레이티드 Ａｍｐｋ 조절자

Also Published As

Publication number Publication date
CA2721025C (en) 2016-07-26
UA103321C2 (ru) 2013-10-10
JP5592348B2 (ja) 2014-09-17
ECSP10010599A (es) 2010-12-30
CN101998853B (zh) 2015-02-11
CO6300954A2 (es) 2011-07-21
JP2011516510A (ja) 2011-05-26
EP2262500A1 (en) 2010-12-22
EP2262500B1 (en) 2016-04-27
HUE027857T2 (en) 2016-11-28
SI2262500T1 (sl) 2016-09-30
BRPI0910439A2 (pt) 2015-09-29
CN101998853A (zh) 2011-03-30
KR20100137563A (ko) 2010-12-30
US20110034505A1 (en) 2011-02-10
CA2721025A1 (en) 2009-10-15
MY155836A (en) 2015-12-15
BRPI0910439B8 (pt) 2021-05-25
PT2262500T (pt) 2016-08-16
ZA201008050B (en) 2011-07-27
BRPI0910439B1 (pt) 2020-10-20
WO2009124636A1 (en) 2009-10-15
NZ589136A (en) 2012-06-29
AU2009235784A1 (en) 2009-10-15
PL2262500T3 (pl) 2016-09-30
KR101630466B1 (ko) 2016-06-14
US8563729B2 (en) 2013-10-22
ES2584278T3 (es) 2016-09-26
HK1155955A1 (en) 2012-06-01
AU2009235784B2 (en) 2013-09-19
HRP20160907T1 (hr) 2016-09-23
EA017756B1 (ru) 2013-02-28
EA201001585A1 (ru) 2011-06-30
IL208067A (en) 2015-05-31
DK2262500T3 (en) 2016-08-15
IL208067A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
MY155836A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
MY160357A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
ATE517882T1 (de) Chinolinderivate
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
TW200637817A (en) 5-aminoindole derivatives
SI1745010T1 (sl) Substituirani cikloheksil-1,4-diaminski derivati
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
EA201001095A1 (ru) Соединение (r)-n*6*-этил-6,7-дигидро-5н-индено[5,6-d]тиазол-2,6-диамин и его применение в качестве антипсихотического средства
WO2010129848A3 (en) 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamides
MX2007010841A (es) 8-pirrolidinobenzimidazoles biciclicos sustituidos, un metodo para su produccion y su uso como medicamentos.
BRPI0807799A2 (pt) " derivados de 2-piperazin-1-il-3h-imidazo{4,5-b]piridina".
MX2009013240A (es) Derivados de carboxamida heterociclicos, su uso farmaceutico y composiciones.
TN2010000373A1 (en) The present invention provides oxadiazoanthracene
TN2010000488A1 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
FG Grant or registration